T0	Outcomes 335 353	antitumor activity
T1	Outcomes 858 958	tumor shrinkage before crossover assessed by investigator (IR) and independent central review (ICR).
T2	Outcomes 1102 1132	mean tumor shrinkage by IR/ICR
T3	Outcomes 1210 1233	Objective response rate
T4	Outcomes 1302 1334	Comparable disease control rates
T5	Outcomes 1450 1469	â‰¥3 drug-related AEs
T6	Outcomes 1478 1492	were rash/acne
T7	Outcomes 1505 1520	8.3%), diarrhea
T8	Outcomes 1540 1564	and stomatitis/mucositis
T9	Outcomes 1635 1682	with DRAEs leading to treatment discontinuation
T10	Outcomes 1738 1771	II, disease control rate (IR/ICR)
T11	Outcomes 1854 1879	showed antitumor activity
T12	Outcomes 2091 2117	sustained clinical benefit